title: Harnessing nanomedicine for mucosal theranostics--a silver bullet at last?
abstract: Inflammatory bowel disease (IBD) has been extensively studied in the last four decades both in animal models and humans. The treatment options remain disappointing, nonspecific, and associated with multiple systemic adverse effects. In this Perspective, we highlight issues related to emerging nanotechnologies designed particularly for treatment and disease management of IBD and discuss potential therapeutic target options with novel molecular imaging modalities.
authors.affiliation: Department of Immunology, Weizmann Institute of Sciences, Rehovot 76100, Israel. eran.elinav@weizmann.ac.il
authors.forename: Eran
authors.initials: E
authors.lastname: Elinav
authors.forename: Dan
authors.initials: D
authors.lastname: Peer
mesh_terms: D006801:Humans; D015212:Inflammatory Bowel Diseases / Q000175:diagnosis* / Q000188:drug therapy*; D007413:Intestinal Mucosa / Q000187:drug effects* / Q000473:pathology*; D057054:Molecular Imaging / Q000379:methods*; D050997:Nanomedicine / Q000639:trends*; D053758:Nanoparticles / Q000627:therapeutic use*